Type: drug
Status: Active — TRIUMPH Program Enrollment
Developer: Eli Lilly
Retatrutide is the first triple incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data showed up to 24.2% body weight reduction at 48 weeks. The TRIUMPH Phase 3 program (2025-2026) evaluates glycemic control in T2D with concurrent weight loss and cardiovascular outcomes.
Triple agonism: GIP activation enhances insulin secretion and lipid metabolism; GLP-1 suppresses appetite and augments glucose-dependent insulin release; glucagon receptor activation increases energy expenditure and hepatic lipid oxidation.
Year: 2025-2026